Iovance Biotherapeutics received FDA approval for a cancer drug, with its stock performance contrasting against the S&P 500 slide.
1 report, 1 independent
Updated Aug 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Iovance Biotherapeutics received FDA approval for a cancer drug, with its stock performance contrasting against the S&P 500 slide.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Iovance Biotherapeutics
American biopharmaceutical startup
-
S&P
Japanese company
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA approved a new cancer drug in Massachusetts on October 21, 2026.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- FDA approval expands patient access to therapies for ACCORD.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
Coverage
Newest first; wire copies grouped- Motley FoolWhy Iovance Biotherapeutics Stock Was Climbing Today Iovance secured conditional approval for its cancer drug in Canada. This is pending the outcome of late-stage clinical trials. 10 stocks we like b